Breaking News, Financial News

Financial Report: Novo Nordisk

Revenues up 17% in first half

Novo Nordisk
 
1H Revenues: $6.2 billion (+17%)

1H Earnings: $1.7 billion (+22%)

Comments: Modern insulin sales increased 20% to $2.8 billion, with sales of Victoza up 82% to $717 million. Biopharmaceutical segment sales were $1.4 billion, up 6%. Sales in North America increased by 29%. International sales increased 19%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters